Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal
Raises Outlook After Pact For ODM-208
The Finnish group has concluded an extensive search to partner its first-in-class CYP11A1 inhibitor, banking an impressive $290m upfront fee for the Phase II drug which is being evaluated for metastatic castration-resistant prostate cancer.
